CardiovascularFDA Approved

Brain Natriuretic Peptide (BNP)

Intravenous

Overview

Brain natriuretic peptide, despite its name, is a 32-amino acid hormone secreted predominantly by ventricular cardiomyocytes in response to ventricular stretch and pressure overload. It activates guanylyl cyclase A receptors to promote vasodilation, natriuresis, and suppression of the renin-angiotensin-aldosterone and sympathetic nervous systems.

Mechanism of Action

BNP and its N-terminal fragment (NT-proBNP) are widely used as diagnostic and prognostic biomarkers in heart failure..

Research Summary & Key Findings

Nesiritide, a recombinant form of human BNP, received FDA approval in 2001 for acute decompensated heart failure based on hemodynamic improvement in clinical trials. BNP measurement is incorporated into heart failure diagnostic guidelines following extensive validation studies, including the Breathing Not Properly study (NEJM, 2002), which established its utility in emergency department assessment of dyspnea.

Clinical Status

FDA Approved

Brain Natriuretic Peptide (BNP) has received FDA approval and is available for clinical use under appropriate medical supervision. Consult a qualified healthcare provider for prescribing information.

Administration Routes

Intravenous

Related Peptides in Cardiovascular

Find a Provider

Find a verified provider who offers Brain Natriuretic Peptide (BNP) therapy in your area.

Browse Provider Map

Find a Pharmacy

Browse PCAB-accredited and FDA 503B-registered compounding pharmacies that supply Brain Natriuretic Peptide (BNP).

Pharmacy Directory

Join the Association

Access exclusive peptide protocols, provider resources, and community support.

List Your Practice

Disclaimer: This information is provided for educational and research purposes only. It is not intended as medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting any peptide therapy. The Peptide Association does not endorse or recommend any specific treatment protocol.